MedPath

Cyproheptadine Hydrochloride

Cyproheptadine Hydrochloride Tablets, USP

Approved
Approval ID

c5e9e983-d0d2-4f87-beae-0d853ca43983

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 8, 2022

Manufacturers
FDA

Rising Pharma Holdings, Inc.

DUNS: 835513529

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cyproheptadine Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code16571-805
Application NumberANDA207555
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cyproheptadine Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateFebruary 8, 2022
FDA Product Classification

INGREDIENTS (5)

LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CYPROHEPTADINE HYDROCHLORIDEActive
Quantity: 4 mg in 1 1
Code: NJ82J0F8QC
Classification: ACTIB
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cyproheptadine Hydrochloride - FDA Drug Approval Details